Cargando…
Management of metastatic endometrial cancer: physicians’ choices beyond the first line after approval of checkpoint inhibitors
INTRODUCTION: Endometrial cancer (EC) represents 3.4% of all newly diagnosed cancer cases and is responsible for 2.1% of all cancer-related deaths. Approximately 10%–15% of women with EC are diagnosed with advanced-stage disease, resulting in a reported 5-year survival rate of only 17% for those wit...
Autores principales: | Arezzo, Francesca, Giannone, Gaia, Castaldo, Daniele, Scotto, Giulia, Tuninetti, Valentina, Turinetto, Margherita, Bartoletti, Michele, Mammoliti, Serafina, Artioli, Grazia, Mangili, Giorgia, Salutari, Vanda, Lorusso, Domenica, Cormio, Gennaro, Loizzi, Vera, Zamagni, Claudio, Savarese, Antonella, Di Maio, Massimo, Ronzino, Graziana, Pisano, Carmela, Pignata, Sandro, Valabrega, Giorgio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10538538/ https://www.ncbi.nlm.nih.gov/pubmed/37781174 http://dx.doi.org/10.3389/fonc.2023.1247291 |
Ejemplares similares
-
Management of Metastatic Endometrial Cancer: Physicians’ Choices Beyond the First Line. A MITO Survey
por: Giannone, Gaia, et al.
Publicado: (2022) -
The Role of PARP Inhibitors in the Ovarian Cancer Microenvironment: Moving Forward From Synthetic Lethality
por: Turinetto, Margherita, et al.
Publicado: (2021) -
Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy
por: Giannone, Gaia, et al.
Publicado: (2020) -
Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status
por: Gadducci, Angiolo, et al.
Publicado: (2019) -
Biomarkers of Central Nervous System Involvement from Epithelial Ovarian Cancer
por: Scotto, Giulia, et al.
Publicado: (2021)